Pile of newspapers on white background

Blog

image-

LineaRx Stands Ready to Support the Reshoring of Drug Development and Manufacturing with U.S.-Produced Synthetic DNA

Posted on

Pivot to U.S.-based Supply Chain for Critical Input Materials Completed STONY BROOK, N.Y. April 21, 2025 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the “Company”), a leader in PCR-based DNA technologies, today announced that LineaRx, Inc., the Company’s majority-owned subsidiary, has completed a long-term initiative to source critical input materials for its […]

Read More email

image-

2nd Annual DNA Process Development & Manufacturing Summit: March 26-27

Posted on

LineaRx, an Applied DNA company, will showcase its Linea™ IVT and Linea™ DNA platforms at the upcoming DNA Process Development & Manufacturing Summit, in Boston, MA. March 26-27, 2025 Team members will be available during the show for one-on-one meetings. Email info@adnas.com to schedule a meeting today!

Read More email

image-

World Vaccine Congress: April 21-24

Posted on

LineaRx, an Applied DNA company, will showcase its Linea™ IVT and Linea™ DNA platforms at the upcoming World Vaccine Congress, to be held April 21 – 24, 2025 at the Walter E. Washington Convention Center in Washington, D.C. We are exhibiting at Booth 479. Team members will be available during the show for one-on-one meetings. Email […]

Read More email

image-

Fast-tracking mRNA Medicines: A synthetic DNA platform to optimize mRNA production

Posted on

AUTHORS Atsuko Sangria, PhD, Director, Drug Substance Process Development, Kudo Biotechnology Aaron Chung, Director, Nucleic Acid Platforms, LineaRx/Applied DNA SciencesYuhua Sun, Executive Director of R&D, LineaRx/Applied DNA Sciences Overview mRNA therapeutics offer benefits far beyond pandemic vaccines, including cancer vaccines, protein replacement, and cell and gene therapies. Swift development and delivery are crucial, as delays […]

Read More email

image-

4th Annual Circular & Self-Amplifying RNA Therapeutics Summit: May 28-29

Posted on

Realizing the full clinical potential of circular and self-amplifying RNAs across infectious diseases, CAR-T therapy, gene therapy and beyond with improved efficacy, functionality and immunogenicity. May 28 – 29, 2025 • Boston, MA

Read More email

image-

Applied DNA Completes Buildout of GMP Facility for LineaDNA IVT Templates

Posted on

Signals Start of New Commercialization Phase for LineaRx SubsidiaryCompany Negotiating GMP Supply AgreementCompany Reaffirms Strategic Restructuring Timeline STONY BROOK, N.Y., January 10, 2025 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, today announced the completion of the buildout of its new Good Manufacturing Practices (GMP) manufacturing facility (the “facility”) […]

Read More email

image-

Applied DNA Customer ÚHKT Initiates Phase I Clinical Trial for Rapidly Manufacturable CAR T-cell Therapy Produced from LineaDNA

Posted on

Regulatory Approval Showcases Clinical Advancement of Linea DNA™ as a Rapid and Effective Means of Producing CAR-T cell Therapies STONY BROOK, N.Y., December 18, 2024 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, announced that the State Institute for Drug Control of the Czech Republic […]

Read More email

image-

5th Annual mRNA-based Therapeutics Summit: July 21-23

Posted on

Fast track your mRNA-based vaccines and therapeutics from discovery to commercialization by ensuring targeted delivery, durability and tolerable immunogenicity across all disease indicators. July 21-23, 2025 • Boston, MA

Read More email

image-

mRNA Process Development and Manufacturing Summit 2025

Posted on

LineaRx, an Applied DNA company, will showcase its Linea™ IVT and Linea™ DNA platforms at the 2025 mRNA Process Development & Manufacturing Summit, this September in Boston, MA.

Read More email